{
  "title": "Orban ITN012AI: Evaluation of Diabetes Vaccine IBC-VSO1 in Newly Diagnosed Diabetics",
  "identifier": {
    "identifier": "http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY568",
    "identifierSource": "http://www.immport.org"
  },
  "producedBy": {  "name": "Orban ITN012AI: Evaluation of Diabetes Vaccine IBC-VSO1 in Newly Diagnosed Diabetics",
  "performedBy": [
    {
      "firstName": "Tihamer",
      "lastName": "Orban",
      "email": "torban@joslin.harvard.edu",
      "affiliations": [
          {
             "name": "Joslin Diabetes Center"
          }
      ],
      "roles": [
          {
             "value": "Principal Investigator"
          }
      ]
    }
  ],
  "studyGroups": [
        {
          "name": "IBC-VSO1",
          "size": 6
        },
        {
          "name": "Placebo-VSO2",
          "size": 6
        }
  ],
  
  "selectionCriteria": [
        {
          "category": "Inclusion",
          "values": [
              "Diagnosed with type 1 diabetes mellitus within 3 months prior to study entry"
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "Positive for IAA, GAD65, or IA2 antibodies or positive for GAD65 or IA2 antibodies after 2 weeks of starting insulin treatment"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "History of treatment with any oral hypoglycemic agent for more than 3 months"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Ongoing use of medications know to influence glucose tolerance"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "History of immunosuppressive or steroid therapy for more than 3 months within the 2 years prior to study entry"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Severe active liver, heart, kidney or immunodeficiency disease that may limit life expectancy or may require immunosuppression during the study"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Prior complications related to routine vaccinations"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Prior participation in a trial for prevention of type 1 diabetes mellitus.  Individuals who are know to have been in the placebo arm of a completed prevention trial are not excluded."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Any condition that may interfere with a participant's ability to comply with the study"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Pregnancy or planned pregnancy within the time frame of the study"
          ]
        }
  ],
  
  "types": [
      {
          "value": "Interventional"
      }
  ]
  },
  "creators": [
    {
      "firstName": "Tihamer",
      "lastName": "Orban",
      "email": "torban@joslin.harvard.edu",
      "affiliations": [
          {
             "name": "Joslin Diabetes Center"
          }
      ],
      "roles": [
          {
             "value": "Principal Investigator"
          }
      ]
    },
    {
      "name": "Immune Tolerance Network",
      "extraProperties": [
        {
          "category": "Catgory",
          "values": [
            {
              "value": "DAIT"
            }
          ]
        },
        {
          "category": "External Id",
          "values": [
            {
              "value": "N/A1"
            }
          ]
        },
        {
          "category": "Description",
          "values": [
            {
              "value": "Immune Tolerance Network"
            }
          ]
        }
      ]
    }
  ],
  
  "primaryPublications": [
    {
      "identifier":
        {
          "identifier": "19931408",
          "identifierSource": "pubmed"
        },
      "authorsList": "Orban T(1), Farkas K, Jalahej H, Kis J, Treszl A, Falk B, Reijonen H, Wolfsdorf J, Ricker A, Matthews JB, Tchao N, Sayre P, Bianchine P.",
      "title": "Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes  mellitus by insulin B-chain immunotherapy.",
      "publicationVenue": "J Autoimmun.",
      "dates": [
        {
          "date": "2010",
          "type": { "value": "publication year" }
        }
      ]
    }
  ],
  "types": [
      {
        "value": "Clinical Trial"
      },
      {
        "value": "Interventional"
      },
      {
        "value": "Autoimmune"
      }
  ],
  "dates": [
      {
          "date": "2003-03-01",
          "type": {
              "value": "actual_start_date"
          }
      },
      {
          "date": "2016-06-17",
          "type": {
              "value": "final_public_release_date"
          }
      }
  ],
  "availability": "Available for download after registration with ImmPort",
  "refinement": "Curated",
  "dimensions": [{
        "name": {
            "value": "Comprehensive Metabolic Panel"
        }
      },{
        "name": {
            "value": "Blood Cell Count with Differential"
        }
      },{
        "name": {
            "value": "Urinalysis"
        }
      },{
        "name": {
            "value": "Chemistry Test"
        }
      }
      
  ],
  
  "distributions": [
      {
          "identifier": {
              "identifier": "SDY568",
              "identifierSource": "ImmPort"
          },
          "title": "Orban ITN012AI: Evaluation of Diabetes Vaccine IBC-VSO1 in Newly Diagnosed Diabetics",
          "access": {
              "landingPage": "http://www.immport.org",
              "accessURL": "http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY568",
              "types": [
                  {
                      "value": "Download tab separated files"
                  },
                  {
                      "value": "Download MySQL files and schema"
                  }
              ],
              "authorizations": [
                {
                    "value": "Registraton with ImmPort required"
                }
              ]
          },
          "storedIn": {
              "name": "ImmPort",
              "types": [
                {
                  "value": "primary repository"
                }
              ]
         },
         "licenses": [
           {
             "name": "ImmPort User Agreement",
             "version": "1.0",
             "extraProperties": [
               {
                 "category": "Link to User Agreement",
                 "values": [
                   {
                     "value": "http://www.immport.org/agreement"
                   }
                 ]
               }
             ]
           }
         ]
      }
  ],
  "acknowledges": [
    {
      "identifier": {
        "identifier": ""
      },
      "name": "Immune Tolerance Network",
      "extraProperties": [
        {
          "category": "Link",
          "values": [
            {
              "value": "https://www.fpds.gov/ezsearch/search.do?s=FPDS&q=%22IT+strategy%22+OR+%22enterprise+architecture%22+DEPARTMENT_FULL_NAME%3A%22HEALTH+AND+HUMAN+SERVICES%2C+DEPARTMENT+OF%22+PIID%3A%22HHSD2002011F41972%22+VENDOR_ADDRESS_ZIP_CODE%3A%22221027508%22+GLOBAL_VENDOR_NAME%3A%22GAVER+TECHNOLOGIES++INC.%22+VENDOR_FULL_NAME%3A%22VANGENT%2C+INC.%22+TREASURY_ACCOUNT_SYMBOL%3A%22750885%22+CONTRACTING_OFFICE_NAME%3A%22NIH%2C+NIAID+DEA+OA+OFC+ACQUISITIONS%22+VENDOR_FULL_NAME%3A%22ST.+LOUIS+UNIVERSITY%22+PRODUCT_OR_SERVICE_CODE%3A%22AB93%22+PRINCIPAL_NAICS_CODE%3A%22325414%22+VENDOR_ADDRESS_ZIP_CODE%3A%22277088990%22+PIID%3A%22HHSN266200500019C%22&indexName=awardfull&templateName=1.4.4"
            }
          ]
        }
      ]}
  ],
  "licenses": [
    {
      "name": "ImmPort User Agreement",
      "version": "1.0",
      "extraProperties": [
        {
          "category": "Link to User Agreement",
          "values": [
            {
              "value": "http://www.immport.org/agreement"
            }
          ]
        }
      ]
    }
  ],
  "description": "IBC-VSO1 vaccine, a synthetic metabolically inactive form of insulin is being evaluated as means of preventing pancreatic beta-cell destruction in newly diagnosed type 1 diabetes patients."
}
